DNTH
Price
$34.70
Change
+$0.24 (+0.70%)
Updated
Oct 7 closing price
Capitalization
1.37B
OCUL
Price
$11.52
Change
+$0.55 (+5.01%)
Updated
Oct 7 closing price
Capitalization
2.44B
33 days until earnings call
Interact to see
Advertisement

DNTH vs OCUL

Header iconDNTH vs OCUL Comparison
Open Charts DNTH vs OCULBanner chart's image
Dianthus Therapeutics
Price$34.70
Change+$0.24 (+0.70%)
Volume$326.07K
Capitalization1.37B
Ocular Therapeutix
Price$11.52
Change+$0.55 (+5.01%)
Volume$3.73M
Capitalization2.44B
DNTH vs OCUL Comparison Chart in %
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. OCUL commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Hold and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (DNTH: $34.70 vs. OCUL: $11.52)
Brand notoriety: DNTH and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 44% vs. OCUL: 133%
Market capitalization -- DNTH: $1.37B vs. OCUL: $2.44B
DNTH [@Biotechnology] is valued at $1.37B. OCUL’s [@Biotechnology] market capitalization is $2.44B. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • DNTH’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, DNTH is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 3 bullish TA indicator(s).

  • DNTH’s TA Score: 4 bullish, 4 bearish.
  • OCUL’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, DNTH is a better buy in the short-term than OCUL.

Price Growth

DNTH (@Biotechnology) experienced а -11.82% price change this week, while OCUL (@Biotechnology) price change was -1.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was +15.97%, and the average quarterly price growth was +89.17%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+8.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.44B) has a higher market cap than DNTH($1.37B). DNTH YTD gains are higher at: 59.174 vs. OCUL (34.895). DNTH has higher annual earnings (EBITDA): -129.49M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. DNTH (257M). DNTH has less debt than OCUL: DNTH (1.33M) vs OCUL (76.9M). OCUL has higher revenues than DNTH: OCUL (56.7M) vs DNTH (4.85M).
DNTHOCULDNTH / OCUL
Capitalization1.37B2.44B56%
EBITDA-129.49M-200.5M65%
Gain YTD59.17434.895170%
P/E Ratio3.24N/A-
Revenue4.85M56.7M9%
Total Cash257M391M66%
Total Debt1.33M76.9M2%
FUNDAMENTALS RATINGS
DNTH vs OCUL: Fundamental Ratings
DNTH
OCUL
OUTLOOK RATING
1..100
7612
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
49
Fair valued
PROFIT vs RISK RATING
1..100
2985
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
3752
P/E GROWTH RATING
1..100
65100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (49) in the Pharmaceuticals Other industry is in the same range as DNTH (60) in the null industry. This means that OCUL’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's Profit vs Risk Rating (29) in the null industry is somewhat better than the same rating for OCUL (85) in the Pharmaceuticals Other industry. This means that DNTH’s stock grew somewhat faster than OCUL’s over the last 12 months.

DNTH's SMR Rating (97) in the null industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that DNTH’s stock grew similarly to OCUL’s over the last 12 months.

DNTH's Price Growth Rating (37) in the null industry is in the same range as OCUL (52) in the Pharmaceuticals Other industry. This means that DNTH’s stock grew similarly to OCUL’s over the last 12 months.

DNTH's P/E Growth Rating (65) in the null industry is somewhat better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that DNTH’s stock grew somewhat faster than OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNTHOCUL
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LEVOX12.64N/A
N/A
Lazard US Equity Concentrated Open
ITHCX43.56N/A
N/A
Invesco Technology C
GCEUX103.66N/A
N/A
Green Century Equity Institutional
FMDRX33.85N/A
N/A
Franklin Mutual Global Discovery R6
SRUAX15.48N/A
N/A
Meeder Spectrum Adviser

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with XNCR. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+0.70%
XNCR - DNTH
47%
Loosely correlated
+2.04%
SYRE - DNTH
45%
Loosely correlated
-3.90%
OCUL - DNTH
44%
Loosely correlated
+5.01%
VRDN - DNTH
44%
Loosely correlated
+0.82%
CGON - DNTH
43%
Loosely correlated
-0.34%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+5.01%
EYPT - OCUL
64%
Loosely correlated
-2.72%
IDYA - OCUL
56%
Loosely correlated
-2.07%
NRIX - OCUL
54%
Loosely correlated
-1.21%
DNLI - OCUL
54%
Loosely correlated
-2.10%
NUVL - OCUL
54%
Loosely correlated
-0.56%
More